Jeffrey S. Flier net worth and biography

Jeffrey Flier Biography and Net Worth

Director of Scholar Rock

Jeffrey S. Flier MD has served as a member of our board of directors since October 2016. Since August 2016, Dr. Flier has served as the Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor, and from 2007 to August 2016 served as the twenty-first Dean of the Faculty of Medicine at Harvard University. Previously, from 2002 to 2007, Dr. Flier served as Chief Academic Officer of Beth Israel Deaconess Medical Center and served as Harvard Medical School Faculty Dean for Academic Programs. An elected member of the National Academy of Medicine and a fellow of the American Academy of Arts and Sciences, his many honors include the Eli Lilly Award of the American Diabetes Association, and the Berson Lecture of the American Physiological Society. He was the recipient of the 2005 Banting Medal from the American Diabetes Association, its highest scientific honor. Dr. Flier received his BS from City College of New York and his MD from Mount Sinai School of Medicine with highest academic honors, and he completed his residency training at Mount Sinai School of Medicine.

What is Jeffrey S. Flier's net worth?: The estimated net worth of Jeffrey S. Flier is at least $793.83 thousand as of May 29th, 2025. Dr. Flier owns 24,070 shares of Scholar Rock stock worth more than $793,829 as of June 16th. This net worth approximation does not reflect any other investments that Dr. Flier may own. Learn More about Jeffrey S. Flier's net worth.
How do I contact Jeffrey S. Flier?: The corporate mailing address for Dr. Flier and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Jeffrey S. Flier's contact information.
Has Jeffrey S. Flier been buying or selling shares of Scholar Rock?: During the last ninety days, Jeffrey S. Flier has sold $180,609.75 in Scholar Rock stock. Most recently, Jeffrey S. Flier sold 6,075 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.73, for a transaction totalling $180,609.75. Following the completion of the sale, the director now directly owns 24,070 shares of the company's stock, valued at $715,601.10. Learn More on Jeffrey S. Flier's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, insiders at the sold shares 26 times. They sold a total of 2,173,013 shares worth more than $68,785,495.77. The most recent insider tranaction occured on May, 29th when Director Jeffrey S Flier sold 6,075 shares worth more than $180,609.75. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 5/29/2025.

Jeffrey S. Flier Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/29/2025	Sell	6,075	$29.73	$180,609.75	24,070
10/1/2021	Sell	6,000	$30.89	$185,340.00
9/20/2021	Sell	500	$34.09	$17,045.00
7/26/2021	Sell	6,000	$31.66	$189,960.00

Jeffrey S. Flier Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $32.98

$32.03

$33.47

50 Day Range

MA: $30.90

$24.47

$34.42

2 Week Range

Now: $32.98

$6.76

$46.98

Volume

637,122 shs

Average Volume

1,276,937 shs

Market Capitalization

$3.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28